BBAuthors: Aja, P. M.; Advisor: -; Participants: Agu, P. C.; Ezeh, E. M.; Awoke, J. N.; Ogwoni, H. A.; Deusdedit, Tusubira; Ekpono, E. U.; Igwenyi, I. O.; Alum, E. U.; Ugwuja, E. I.; Ibiam, A. U.; Afiukwa, C. A.; Adegboyega, Abayomi Emmanuel (2021)
Results for the binding affinities, docking poses, and the interactions showed that ML2, ML4-6, ML8-15, and MS1-5 are potential inhibitors of DHFR and BCL-2, respectively. In the ADMET profile, ML2 and ML4 showed the best drug-likeness by non-violation of Lipski Rule of Five. ML4-6, ML8, ML11, ML14-15, and MS1, MS3-5 exhibit high GI absorption; ML2, ML4-6, ML8, MS1, and MS5 are blood–brain barrier permeants. ML2, ML4, ML9, ML13, and MS2 do not interfere with any of the CYP450 isoforms. The toxicity profile showed that all the potential inhibitors are non-carcinogenic and non-hERG I (human ether-a-go-go related gene I) inhibitors. ML4, ML11, and MS4 are hepatotoxic and ML7, ML10, and M... 
